{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:44:38Z","timestamp":1770705878196,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Growing interest in the clinical use of cannabidiol (CBD) as adjuvant therapy for pediatric refractory epileptic encephalopathy emphasizes the need for drug treatment optimization. The aim of this study was to characterize the pharmacokinetics of CBD in pediatric patients with refractory epileptic encephalopathy receiving an oil\u2010based oral solution. To evaluate CBD concentrations, six serial blood samples per patient were collected after the morning dose of CBD, at least 21\u00a0days after the beginning of treatment. Twelve patients who received a median (range) dose of 12.2 (5.3\u201019.4) mg\/kg\/d (twice daily) were included in the analysis. Median (range) CBD time to maximum plasma concentration, maximum plasma concentration, and area under the concentration versus time curve up to 6\u00a0hours after dosing were 3.2\u00a0hours (1.9\u20106.2), 49.6\u00a0ng\/mL (14.4\u2010302.0), and 226.3\u00a0ng \u22c5 h\/mL (70.5\u2010861.3), respectively. CBD systemic exposure parameters were in the lower range of previous reports in pediatric patients receiving doses in a similar range. Most of our patients (83%) showed little CBD plasma level fluctuation during a dosing interval, comparable to that encountered after oral administration of an extended release drug delivery system. CDB administration was generally safe and well tolerated, and a novel levothyroxine\u2010CBD interaction was recorded. Similar to other studies, large interindividual variability in CBD exposure was observed, encouraging the use of CBD therapeutic drug monitoring.<\/jats:p>","DOI":"10.1111\/epi.16781","type":"journal-article","created":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T08:59:01Z","timestamp":1607245141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics of cannabidiol in children with refractory epileptic encephalopathy"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-4960","authenticated-orcid":false,"given":"Paulo","family":"C\u00e1ceres Guido","sequence":"first","affiliation":[{"name":"Clinical Pharmacokinetics Unit, Pharmacy Area Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Riva","sequence":"additional","affiliation":[{"name":"Precision Medicine Garrahan Pediatric Hospital Buenos Aires Argentina"},{"name":"National Scientific and Technical Research Council Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-1046","authenticated-orcid":false,"given":"Roberto","family":"Caraballo","sequence":"additional","affiliation":[{"name":"National Scientific and Technical Research Council Buenos Aires Argentina"},{"name":"Department of Neurology Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Neurology Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Huaman","sequence":"additional","affiliation":[{"name":"Department of Neurology Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robinson","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Neurology Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Agostini","sequence":"additional","affiliation":[{"name":"Polyvalent Day Hospital Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Fabiana Delaven","sequence":"additional","affiliation":[{"name":"Polyvalent Day Hospital Garrahan Pediatric Hospital Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"P\u00e9rez Montilla","sequence":"additional","affiliation":[{"name":"National Scientific and Technical Research Council Buenos Aires Argentina"},{"name":"Multidisciplinary Institute for Research on Pediatric Diseases, Parasitology and Chagas Service Buenos Aires Children's Hospital \"Ricardo Gutierrez \" Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Facundo","family":"Garc\u00eda Bournissen","sequence":"additional","affiliation":[{"name":"National Scientific and Technical Research Council Buenos Aires Argentina"},{"name":"Division of Paediatric Clinical Pharmacology Department of Paediatrics Schulich School of Medicine and Dentistry Western University London ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-4731","authenticated-orcid":false,"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[{"name":"Precision Medicine Garrahan Pediatric Hospital Buenos Aires Argentina"},{"name":"National Scientific and Technical Research Council Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1708349"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00624-4"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.06.005"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00869-z"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14608"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005254"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16419"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303720"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.06.021"},{"key":"e_1_2_9_12_1","article-title":"Ultra\u2010fast UHPLC\u2010MS\/MS method development in cannabidiol monitoring","author":"P\u00e9rez\u2010Montilla CA","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"2","key":"e_1_2_9_13_1","first-page":"50","article-title":"Per oral extended release products\u2014an overview","volume":"1","author":"Jayanthi B","year":"2011","journal-title":"J Appl Pharm Sci"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2019-0050"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0034"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2017.1304593"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344336"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1141"},{"key":"e_1_2_9_19_1","article-title":"The interplay between liver first\u2010pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations","author":"Franco V","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.966683"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4172\/2325-9841.1000106"},{"issue":"9","key":"e_1_2_9_22_1","first-page":"2034","article-title":"Loss of carbamazepine suspension through nasogastric feeding tubes","volume":"47","author":"Clark\u2010Schmidt AL","year":"1990","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246254"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16781","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.16781","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:51:09Z","timestamp":1693756269000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.16781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/epi.16781"],"URL":"https:\/\/doi.org\/10.1111\/epi.16781","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,6]]},"assertion":[{"value":"2020-09-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}